Afloqualone

Afloqualone (Arofuto) is a quinazolinone family GABAergic drug and is an analogue of methaqualone developed in the 1970s by a team at Tanabe Seiyaku.[1] It has sedative and muscle-relaxant effects resulting from its agonist activity at the β subtype of the GABAa receptor [2] and has had some clinical use, although it causes photosensitization as a side-effect that can cause skin problems such as dermatitis.[3]

Afloqualone
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
  • none
Legal status
Legal status
  • US: Unscheduled
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H14FN3O
Molar mass283.3 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

See also

References

  1. US 3966731, Inoue I, Oine T, Yamada Y, Tani J, Ishida R, Ochiai T, "2-Fluoromethyl-3-o-tolyl-6-amino-4(3H)-quinazolinone", issued 29 June 1976, assigned to Tanabe Seiyaku Co Ltd
  2. Ochiai T, Ishida R (June 1982). "Pharmacological studies on 6-amino-2-fluoromethyl-3-(O-tolyl)-4(3H)-quinazolinone (afloqualone), a new centrally acting muscle relaxant. (II) Effects on the spinal reflex potential and the rigidity". Japanese Journal of Pharmacology. 32 (3): 427–38. doi:10.1254/jjp.32.427. PMID 7109348.
  3. Ishikawa T, Kamide R, Niimura M (June 1994). "Photoleukomelanodermatitis (Kobori) induced by afloqualone". The Journal of Dermatology. 21 (6): 430–3. doi:10.1111/j.1346-8138.1994.tb01768.x. PMID 8064007. S2CID 7486566.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.